Therapeutic Applications of Sertal Compuesto

Sertal Compuesto is a fixed-dose combination medication designed to address gastrointestinal and genitourinary symptoms. It combines an antispasmodic agent, propinox hydrochloride, with an analgesic, usually clonixinate or paracetamol, to provide a dual mechanism of action.

Principal Uses

The primary function of this medication is the relief of pain associated with spasms of the smooth muscle. Smooth muscle is found in the walls of hollow organs, and involuntary contractions (spasms) in these areas can result in significant discomfort or cramping. The medication is commonly used for:

• Gastrointestinal Colic: Management of sharp, localized abdominal pain resulting from spasms in the digestive tract.
• Biliary Colic: Relief of pain associated with contractions or obstructions in the gallbladder or bile ducts.
• Renal and Urinary Colic: Treatment of intense pain caused by spasms in the ureters or bladder, often associated with the passage of stones.
• Menstrual Pain (Dysmenorrhea): Alleviation of uterine cramping and associated pelvic pain.

Benefits of Combination Therapy

The integration of two different active ingredients offers a comprehensive approach to symptom management:

• Antispasmodic Action: Propinox hydrochloride acts directly on the smooth muscle fibers, reducing their tone and frequency of contraction. This helps to relax the affected organ and address the root cause of the cramp.
• Analgesic Support: The pain-relieving component addresses the sensory perception of pain. By blocking specific inflammatory pathways or pain signals, it provides comfort while the antispasmodic works on the muscular tension.
• Rapid Symptom Control: The combination is formulated to work quickly, aiming to reduce the intensity of acute pain episodes and restore a level of comfort to the patient during spastic events.

The eligibility profile for Sertal Compuesto is governed by the official contraindications for its dual components: Clonixin (NSAID) and Pargeverine (spasmolytic).

Populations Excluded or Restricted from Use

Classification	Population/Condition	Regulatory Basis
Absolute Contraindication	Known Hypersensitivity to either active ingredient or other NSAIDs.	Spasmolytic & NSAID Components
	Active Gastrointestinal Bleeding, Perforation, or Peptic Ulceration (current or history).	NSAID Component
	Severe Hepatic or Severe Renal Impairment.	Both Components
	Narrow-Angle Glaucoma or Myasthenia Gravis.	Spasmolytic Component
Not Recommended	Pediatric Patients (children and adolescents).	Use Not Established
	Pregnancy (especially the third trimester) and Lactation.	NSAID Component Risk
Restricted Use/Caution	Older Adults (Geriatric) due to increased risk of adverse events.	General NSAID Warning
	Patients with Cardiovascular Disease or risk factors (due to thrombotic risk).	NSAID Component

The drug is officially indicated for the adult population provided none of the above contraindications or severe risk factors are present. Regulatory documentation specifies absolute prohibition for populations with severe organ dysfunction, active GI disease, and certain nervous system conditions sensitive to the spasmolytic agent.

The official regulatory profile for Sertal Compuesto (Clonixin, Pargeverine) establishes interaction constraints based on the distinct pharmacological properties of its two active components. These interactions are formally classified into contraindicated combinations and clinically significant interactions affecting risk and efficacy.

Contraindicated Combinations

Co-administration is formally prohibited with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This restriction is due to an additive pharmacodynamic risk of serious gastrointestinal adverse events, including ulceration and hemorrhage. Furthermore, certain anticholinergic agents are restricted or contraindicated, which addresses the potential for severe, additive anticholinergic effects from the Pargeverine component.

---

Clinically Significant Interactions

Interactions affecting risk and efficacy include the documented increased risk of bleeding and hemorrhage when the product is co-administered with Anticoagulants or Antiplatelet Agents. The Clonixin component is noted to reduce the intended therapeutic effect of Antihypertensive Agents and Diuretics.

Pharmacokinetic interactions are formally documented where the drug decreases the renal excretion rate of substances like Lithium and Methotrexate, leading to increased systemic exposure and potential toxicity. Additionally, the label documents that alcohol may enhance central nervous system depressant effects, and interaction risks are formally noted as heightened in patients with Severe Renal Impairment.

Sertal Compuesto functions through a dual pharmacodynamic mechanism involving neurotropic and musculotropic actions on smooth muscle, complemented by inhibition of prostaglandin synthesis. This dual approach targets pathways driving both smooth muscle hypermotility and inflammatory signaling.

---

Modulation of Muscarinic Receptor Signaling

The component Propinox acts as a moderate, non-selective antagonist of muscarinic receptors. This interaction suppresses the release of acetylcholine and subsequent cholinergic signaling that mediates overactivity in visceral smooth muscle. The effect is a resulting decrease in smooth muscle tone within targeted pathways of the gastrointestinal and genitourinary systems.

---

Direct Smooth Muscle Modulation

Propinox also exerts a musculotropic mechanism via a direct action on smooth muscle cell fibers, independent of neural input. This process modifies cellular pathways to induce a reduction of smooth muscle contraction force, thereby modulating hypermotility-associated signaling.

---

Cyclooxygenase Enzyme Pathway Inhibition

The component Clonixin lysine acts by inhibiting the cyclooxygenase (COX) enzyme. This interaction modifies early molecular steps that limit the production of prostaglandins, which are key lipid mediators in inflammatory and nociceptive signaling.

Administration Guidelines for Sertal Compuesto

Sertal Compuesto is provided in an oral dosage form containing Propinox hydrochloride 10 mg and Clonixinato de lisina 125 mg.

Administration Scope	Statement
Route of Administration	Oral.
Dosing Schedule	Adults and children over 12 years: 1 to 2 coated tablets.
Frequency	3 to 4 times per day.
Maximum Dose	The maximum dose is 6 coated tablets in 24 hours.
Preparation	Ingest the coated tablets whole, without chewing, and with an adequate amount of liquid.
Timing in Relation to Meals	Ingestion with meals is recommended to reduce possible stomach discomfort.
Age-Group Rules	The medication is intended for adults and children older than 12 years of age.

Instruction Classifications

Classification	Detail
Administration Method Type	Oral (Tablet).
Frequency Pattern	Defined-interval dosing (3 to 4 times per day), not as-needed.
Use-Context Constraints	Administration with food is recommended to minimize gastric issues.

Resulting Procedural Structure

The instruction defines a structured daily protocol for use. The process involves a fixed sequence of steps:

• Step 1: Verify the appropriate dosage (1 or 2 tablets) based on the current regimen.
• Step 2: Take the prescribed number of coated tablets with sufficient liquid.
• Step 3: Swallow the tablets whole without breaking or chewing them.
• Step 4: Repeat the administration 3 to 4 times per day, ensuring the total 24-hour dose does not exceed 6 tablets.

This protocol ensures consistent and standardized drug delivery, establishing clear boundaries for the daily intake and the physical handling of the oral dosage form.

Sertal Compuesto: Recent Clinical Evidence

Evidence for Acute Pain Associated with Renal Colic

Research has explored the combination of an NSAID (Clonixin) and a spasmolytic (Pargeverine) for acute episodes of pain associated with renal colic. Studies primarily involved adult patients in emergency settings, examining outcomes related to physical discomfort, such as changes in pain intensity (e.g., VAS) and the need for rescue analgesia. Much of the data relies on extrapolation from similar NSAID and spasmolytic pairings, and large-scale Randomized Controlled Trials (RCTs) specifically on the Clonixin-Pargeverine combination are limited.

Evidence for Acute Pain Associated with Dysmenorrhea

The combination was evaluated in research exploring how symptoms change over time for dysmenorrhea. Studies included women of reproductive age, monitoring changes in outcomes related to physical discomfort across short-to-intermediate periods (one to a few cycles). The research base includes studies where a different spasmolytic agent (not Pargeverine) was used, and limited information is available regarding the sustained effect with repeated use.

Evidence for Acute Pain Associated with Biliary Colic

Research has explored the combination for use in acute biliary colic, examining outcomes such as the time required for symptom change during the acute episode. Studies were conducted primarily in adult patients in emergency settings. High-level evidence specific to the Clonixin-Pargeverine combination is limited, and the research often uses evidence extrapolated from other NSAID monotherapies.

Long-Term Studies and Follow-up Duration

Clinical research concerning Sertal Compuesto primarily focuses on the management of acute episodes of pain. Follow-up durations were limited, often assessed within the first few hours or up to 24 hours. There is limited information for long-term outcomes, and the pattern of symptoms with repeated or chronic use is not fully established.

Evidence in Special Populations and Subgroups

Clinical data predominantly derives from studies of otherwise healthy adults presenting with acute, uncomplicated visceral pain. Few data are available regarding certain groups such as older adults, pediatric populations, or individuals with multiple concurrent medical conditions (comorbidities).

What Remains Uncertain in the Research Landscape

For Sertal Compuesto, certainty remains low in several areas of the evidence base. Comparative evidence is lacking, and the research often relies on extrapolation. Consequently, research provides context but not individual predictions, and long-term effects are not fully established.

Key Studies & References World Health Organization Collaborating Centre for Drug Statistics Methodology: Anatomical Therapeutic Chemical (ATC) Classification System

Common questions about Sertal Compuesto (FAQ)

---

Q: How is Sertal Compuesto different from a regular, single-ingredient pain reliever?

A: According to official classifications, Sertal Compuesto is a Fixed-Dose Combination (FDC) product that pairs a Nonsteroidal Anti-inflammatory Drug (NSAID) with a spasmolytic agent. This dual action targets both the experience of pain and the underlying muscle cramping, which differs from single-ingredient pain relievers that typically focus on only one therapeutic mechanism.

Q: How quickly does Sertal Compuesto typically start working to relieve symptoms?

A: While specific onset times are not always detailed in regulatory documents, the medication is designed and studied for the management of acute episodes of pain. The components are generally intended to provide a rapid onset of therapeutic effect suitable for addressing acute discomfort.

Q: What is the usual duration of effect for a dose of Sertal Compuesto?

A: Official administration guidelines define a recommended dosing frequency of three to four times per day. This frequency suggests that the effects of a single dose are typically expected to last for the interval between administration times.

Q: Is it necessary to take Sertal Compuesto with food?

A: Regulatory documents recommend taking the medication alongside meals. This recommendation is made to help minimize the possible risk of stomach discomfort or gastrointestinal disturbances that may be associated with the NSAID component.

Q: What should I do if I forget to take a scheduled dose of Sertal Compuesto?

A: General regulatory practices advise that individuals should refer to the product label for missed dose instructions. This typically involves taking the dose when remembered, or omitting it if close to the next scheduled time, to avoid exceeding the maximum daily intake.

Q: Can Sertal Compuesto interact with common supplements like vitamins or herbal products?

A: Official drug labels may not contain specific information regarding every possible vitamin, supplement, or herbal product. For this reason, official information should be reviewed regarding co-administration of supplements due to the potential for unknown interactions.

Q: What is the function of the second ingredient that provides the anti-spasmodic effect?

A: The spasmolytic component is intended to reduce excessive involuntary contractions of smooth muscle fibers. It primarily acts on the gastrointestinal and genitourinary tracts to modulate muscle activity and relieve cramping associated with visceral pain.

Q: Does Sertal Compuesto affect the ability to drive or operate machinery?

A: The official safety profile includes side effects such as dizziness and, rarely, blurred vision. Because these effects can impair concentration and coordination, official documentation describes the need for caution when performing tasks that require full mental alertness, such as driving.

Q: What are the known effects of taking Sertal Compuesto for an extended period of time?

A: Clinical research primarily focuses on the management of acute pain episodes over short durations. Official research summaries indicate that the evidence base for effects and safety concerning repeated or chronic long-term use is limited.

Q: Why is Sertal Compuesto sometimes prescribed for the management of painful periods or menstrual cramps?

A: Research evidence has explored the use of this combination for the pain associated with dysmenorrhea (menstrual cramps). This use aligns with its mechanism, as the NSAID addresses the inflammatory pain and the spasmolytic component is intended to address the related uterine muscle cramping.

Q: Is it normal to feel a little drowsy or dizzy after taking Sertal Compuesto?

A: The official safety profile for the medication classifies dizziness as a commonly reported adverse effect. This effect falls under the category of nervous system disturbances that may be experienced while using the drug.

Q: Can the Sertal Compuesto tablet be crushed or chewed?

A: The official administration guidelines explicitly instruct users to ingest the coated tablets whole. Breaking, crushing, or chewing the tablets is not recommended as this may compromise the intended release of the active ingredients.

Q: What are the possible drug interactions with common blood pressure medications?

A: Official documents note that the Clonixin component of the medicine may interfere with certain treatments. Specifically, it is noted to potentially reduce the intended therapeutic effect of antihypertensive agents (medicines used for blood pressure management).

Q: Does Sertal Compuesto cause changes in sleep patterns, such as insomnia?

A: While the official safety profile mentions general nervous system disturbances, insomnia (difficulty sleeping) is not explicitly listed as a commonly reported adverse reaction. Users should consult the full official documentation for all reported side effects.

Q: Is it possible for Sertal Compuesto to cause heart palpitations or a fast heartbeat?

A: Adverse effects affecting the heart, such as a fast or irregular heartbeat, are typically associated with the anticholinergic properties of the spasmolytic component. Individuals should consult the official safety information for a complete listing of documented adverse effects.

Q: What official resources provide the most detailed regulatory information about Sertal Compuesto?

A: The official prescribing information (drug leaflet or SmPC) provides comprehensive information about the drug. This documentation is released by the national regulatory authority in the specific region where the product is approved.

Q: Is Sertal Compuesto described as gluten-free or lactose-free in its composition?

A: Official regulatory documents contain a complete list of all active and inactive ingredients (excipients) used in the product. This information can be found on the list of inactive ingredients in the official regulatory documents, which must be consulted to confirm the presence of components like lactose or gluten.

Q: What is the correct way to dispose of unused or expired Sertal Compuesto?

A: It is important to handle unused medication safely. While the official labeling does not typically contain household disposal instructions, local drug take-back programs or general municipal disposal guidelines are the customary pathways for managing unused medication.

Q: What is the maximum number of days Sertal Compuesto is usually recommended for use?

A: Clinical evidence and the regulatory profile primarily support the use of the medication for the short-term management of acute pain episodes. The drug is not designed or established for chronic, continuous, long-term use.

Q: Can Sertal Compuesto be taken at the same time as antacids?

A: Regulatory documents may include precautions regarding the co-administration of antacids with medications like this. Antacids can potentially alter the rate or amount of absorption of the drug's active components, which could affect its efficacy.

Q: How should I adjust my activity level while using Sertal Compuesto?

A: Official information advises caution regarding activity levels, especially those that demand full attention. This guidance is based on the potential for side effects such as dizziness or blurred vision, which could compromise safety during complex tasks.

Q: What if I accidentally take two doses close together?

A: Official guidelines establish a clear maximum dose and frequency per 24 hours (for example, a maximum of six coated tablets). Official safety information regarding this scenario emphasizes the importance of not exceeding the maximum dose established per 24 hours.

Q: Is Sertal Compuesto considered a narcotic or controlled substance?

A: The active ingredients in this combination product are classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and a spasmolytic agent. Neither of these components is typically regulated as a narcotic or controlled substance by major international agencies.

Q: How reliable is the research evidence supporting Sertal Compuesto's effectiveness?

A: Official research summaries provide context on the drug's use but note that comparative evidence against other drugs is often lacking. The official documents state that the certainty of the evidence remains low in several areas, with data frequently relying on extrapolation.

Q: What is the meaning or explanation of the 'Compuesto' part of the name?

A: The term 'Compuesto' is used within the brand name to indicate that the product is a Fixed-Dose Combination (FDC). This means it contains two distinct active ingredients to provide a combined therapeutic effect.

How to Store and Dispose of Sertal Compuesto

Official regulatory documents define specific environmental constraints necessary for maintaining the product's integrity and stability.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at a temperature inferior to 30 C
Environment	Must be kept in a dry place
Child Safety	Keep out of the reach of children
Integrity	Do not use after the expiration date printed on the package

Storage must always be within the original container. The required temperature maximum and dry environment ensure the product remains stable until its labeled expiry. Official regulatory labeling does not typically contain explicit household instructions for the disposal of unused or expired product.